We narrowed to 191 results for: t aav

1. pAAV-CAG-DIO-PPO-Venus (AAV5)

   Viral Prep

   #139504-AAV5

   Purpose

   Ready-to-use AAV5 particles produced from pAAV-CAG-DIO-PPO-Venus (#139504). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-PPO-Venus plasmid DNA. CAG-driven, Cre-dependent expression of Venus-tagged parapinopsin. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Michael Bruchas

   Article

   Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

   Promoter

   CAG

   Tags

   Venus

   Available since

   April 10, 2024

   Availability

   Academic Institutions and Nonprofits only

2. pAAV-CAG-GFP (AAV8 trial size)

   Viral Prep

   #37825-AAV8.T

   Purpose

   Ready-to-use AAV8 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Edward Boyden

   Promoter

   CAG

   Tags

   GFP

   Available since

   May 29, 2019

   Availability

   Academic Institutions and Nonprofits only

3. pAAV-CAG-GFP (AAV5 trial size)

   Viral Prep

   #37825-AAV5.T

   Purpose

   Ready-to-use AAV5 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Edward Boyden

   Promoter

   CAG

   Tags

   GFP

   Available since

   May 29, 2019

   Availability

   Academic Institutions and Nonprofits only

4. pAAV-CAG-GFP (AAV9 trial size)

   Viral Prep

   #37825-AAV9.T

   Purpose

   Ready-to-use AAV9 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Edward Boyden

   Promoter

   CAG

   Tags

   GFP

   Available since

   May 29, 2019

   Availability

   Academic Institutions and Nonprofits only

5. pAAV-CAG-GFP (AAV1 trial size)

   Viral Prep

   #37825-AAV1.T

   Purpose

   Ready-to-use AAV1 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Edward Boyden

   Promoter

   CAG

   Tags

   GFP

   Available since

   May 29, 2019

   Availability

   Academic Institutions and Nonprofits only

6. pAAV-CAG-GFP (AAV2 trial size)

   Viral Prep

   #37825-AAV2.T

   Purpose

   Ready-to-use AAV2 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Edward Boyden

   Promoter

   CAG

   Tags

   GFP

   Available since

   May 29, 2019

   Availability

   Academic Institutions and Nonprofits only

7. pAAV-mDlx-GCaMP6f-Fishell-2 (AAV1)

   Viral Prep

   #83899-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-mDlx-GCaMP6f-Fishell-2 (#83899). In addition to the viral particles, you will also receive purified pAAV-mDlx-GCaMP6f-Fishell-2 plasmid DNA. mDlx-driven expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Gordon Fishell

   Article

   Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

   Promoter

   mDlx

   Tags

   None

   Available since

   Nov. 13, 2020

   Availability

   Academic Institutions and Nonprofits only

8. pAAV-mDlx-GCaMP6f-Fishell-2 (AAV9)

   Viral Prep

   #83899-AAV9

   Purpose

   Ready-to-use AAV9 particles produced from pAAV-mDlx-GCaMP6f-Fishell-2 (#83899). In addition to the viral particles, you will also receive purified pAAV-mDlx-GCaMP6f-Fishell-2 plasmid DNA. mDlx-driven expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Gordon Fishell

   Article

   Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

   Promoter

   mDlx

   Tags

   None

   Available since

   Nov. 13, 2020

   Availability

   Academic Institutions and Nonprofits only

9. pAAV-hsyn-flex-Voltron-ST (AAV1)

   Viral Prep

   #119036-AAV1

   Purpose

   Ready-to-use AAV1 particles produced from pAAV-hsyn-flex-Voltron-ST (#119036). In addition to the viral particles, you will also receive purified pAAV-hsyn-flex-Voltron-ST plasmid DNA. Synapsin-driven, cre-dependent expression of genetically encoded fluorescent voltage indicator Voltron1 with a soma-targeting sequence. These AAV preparations are suitable purity for injection into animals.

   Depositor

   Eric Schreiter

   Article

   Abdelfattah et al Science. 2019 Aug 1. pii: science.aav641

   Promoter

   Syn

   Tags

   None

   Available since

   April 10, 2019

   Availability

   Academic Institutions and Nonprofits only

10. AAV phSyn1(S)-FlpO-bGHpA (AAV Retrograde)

    Viral Prep

    #51669-AAVrg

    Purpose

    Ready-to-use AAV Retrograde particles produced from AAV phSyn1(S)-FlpO-bGHpA (#51669). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-FlpO-bGHpA plasmid DNA. hSyn-driven FlpO expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Hongkui Zeng

    Article

    Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

    Promoter

    Syn

    Tags

    None

    Available since

    Oct. 28, 2021

    Availability

    Academic Institutions and Nonprofits only

11. AAV phSyn1(S)-DreO-bGHpA (AAV Retrograde)

    Viral Prep

    #50363-AAVrg

    Purpose

    Ready-to-use AAV Retrograde particles produced from AAV phSyn1(S)-DreO-bGHpA (#50363). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-DreO-bGHpA plasmid DNA. hSyn-driven Dre recombinase expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Hongkui Zeng

    Article

    Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

    Promoter

    Syn

    Tags

    None

    Available since

    Aug. 18, 2020

    Availability

    Academic Institutions and Nonprofits only

12. pAAV-Ef1a-DIO-PPO-Venus (AAV9)

    Viral Prep

    #139505-AAV9

    Purpose

    Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Michael Bruchas

    Article

    Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

    Promoter

    EF1a

    Tags

    Venus (Cre-dependent)

    Available since

    Oct. 28, 2021

    Availability

    Academic Institutions and Nonprofits only

13. pAAV-Ef1a-DIO-PPO-Venus (AAV8)

    Viral Prep

    #139505-AAV8

    Purpose

    Ready-to-use AAV8 particles produced from pAAV-Ef1a-DIO-PPO-Venus (#139505). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-PPO-Venus plasmid DNA. EF1a-driven, Cre-dependent expression of Venus-tagged parapinopsin for spatiotemporal control of inhibitory GPCR signaling cascades. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Michael Bruchas

    Article

    Copits et al Neuron. 2021 Jun 2;109(11):1791-1809.e11

    Promoter

    EF1a

    Tags

    Venus (Cre-dependent)

    Available since

    Sept. 27, 2023

    Availability

    Academic Institutions and Nonprofits only

14. AAV pTRE-FSF-FLEX-EGFP-WPRE-bGHpA (AAV1)

    Viral Prep

    #65453-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from AAV pTRE-FSF-FLEX-EGFP-WPRE-bGHpA (#65453). In addition to the viral particles, you will also receive purified AAV pTRE-FSF-FLEX-EGFP-WPRE-bGHpA plasmid DNA. TRE-driven, Cre and Flp-dependent expression of EGFP. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Hongkui Zeng

    Article

    Madisen et al Neuron. 2015 Mar 4;85(5):942-58. doi: 10

    Promoter

    tetO

    Tags

    EGFP (Cre and Flp-dependent)

    Available since

    Feb. 14, 2022

    Availability

    Academic Institutions and Nonprofits only

15. pAAV-hSyn-EGFP (AAV9 trial size)

    Viral Prep

    #50465-AAV9.T

    Purpose

    Ready-to-use AAV9 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Bryan Roth

    Promoter

    Syn

    Tags

    EGFP

    Available since

    May 29, 2019

    Availability

    Academic Institutions and Nonprofits only

16. pAAV-hSyn-EGFP (AAV2 trial size)

    Viral Prep

    #50465-AAV2.T

    Purpose

    Ready-to-use AAV2 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Bryan Roth

    Promoter

    Syn

    Tags

    EGFP

    Available since

    July 31, 2019

    Availability

    Academic Institutions and Nonprofits only

17. pAAV-hSyn-EGFP (AAV5 trial size)

    Viral Prep

    #50465-AAV5.T

    Purpose

    Ready-to-use AAV5 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Bryan Roth

    Promoter

    Syn

    Tags

    EGFP

    Available since

    June 12, 2019

    Availability

    Academic Institutions and Nonprofits only

18. pAAV-hSyn-EGFP (AAV1 trial size)

    Viral Prep

    #50465-AAV1.T

    Purpose

    Ready-to-use AAV1 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Bryan Roth

    Promoter

    Syn

    Tags

    EGFP

    Available since

    July 12, 2019

    Availability

    Academic Institutions and Nonprofits only

19. pAAV-hSyn-EGFP (AAV8 trial size)

    Viral Prep

    #50465-AAV8.T

    Purpose

    Ready-to-use AAV8 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Bryan Roth

    Promoter

    Syn

    Tags

    EGFP

    Available since

    May 29, 2019

    Availability

    Academic Institutions and Nonprofits only

20. pAAV-mDlx-GFP-Fishell-1 (AAV1)

    Viral Prep

    #83900-AAV1

    Purpose

    Ready-to-use AAV1 particles produced from pAAV-mDlx-GFP-Fishell-1 (#83900). In addition to the viral particles, you will also receive purified pAAV-mDlx-GFP-Fishell-1 plasmid DNA. mDlx-driven expression of GFP in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

    Depositor

    Gordon Fishell

    Article

    Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

    Promoter

    mDlx

    Tags

    GFP

    Available since

    Jan. 26, 2021

    Availability

    Academic Institutions and Nonprofits only